Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 0: clinchem.2008.112789v1, 2009; 10.1373/clinchem.2008.112789
This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
clinchem.2008.112789v1
55/4/641    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Voelkerding, K. V.
Right arrow Articles by Durtschi, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Voelkerding, K. V.
Right arrow Articles by Durtschi, J. D.

Received on October 7, 2008
Accepted on January 29, 2009

Reviews

Next-Generation Sequencing: From Basic Research to Diagnostics

Karl V. Voelkerding 1*, Shale A. Dames 2, Jacob D. Durtschi 2

1 ARUP Institute for Experimental and Clinical Pathology, Salt Lake City, Utah, and Department of Pathology, University of Utah, Salt Lake City, Utah
2 ARUP Institute for Experimental and Clinical Pathology, Salt Lake City, Utah

* To whom correspondence should be addressed. E-mail: voelkek{at} aruplab.com.

BACKGROUND: For the past 30 years, the Sanger method has been the dominant approach and gold standard for DNA sequencing. The commercial launch of the first massively parallel pyrosequencing platform in 2005 ushered in the new era of high-throughput genomic analysis now referred to as next-generation sequencing (NGS).

CONTENT: This review describes fundamental principles of commercially available NGS platforms. Although the platforms differ in their engineering configurations and sequencing chemistries, they share a technical paradigm in that sequencing of spatially separated, clonally amplified DNA templates or single DNA molecules is performed in a flow cell in a massively parallel manner. Through iterative cycles of polymerase-mediated nucleotide extensions or, in one approach, through successive oligonucleotide ligations, sequence outputs in the range of hundreds of megabases to gigabases are now obtained routinely. Highlighted in this review are the impact of NGS on basic research, bioinformatics considerations, and translation of this technology into clinical diagnostics. Also presented is a view into future technologies, including real-time single-molecule DNA sequencing and nanopore-based sequencing.

SUMMARY: In the relatively short time frame since 2005, NGS has fundamentally altered genomics research and allowed investigators to conduct experiments that were previously not technically feasible or affordable. The various technologies that constitute this new paradigm continue to evolve, and further improvements in technology robustness and process streamlining will pave the path for translation into clinical diagnostics.




The following articles in journals at HighWire Press have cited this article:


Home page
Sci SignalHome page
P. H. Huang, A. M. Xu, and F. M. White
Oncogenic EGFR Signaling Networks in Glioma
Sci. Signal., September 8, 2009; 2(87): re6 - re6.
[Abstract] [Full Text] [PDF]


Home page
Brief Funct Genomic ProteomicHome page
K. U. Mir
Sequencing Genomes: From Individuals to Populations
Brief Funct Genomic Proteomic, September 1, 2009; 8(5): 367 - 378.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2009 by the American Association for Clinical Chemistry.